You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, September 2018
|
| DOI | 10.1186/s40425-018-0409-8 |
| Pubmed ID | |
| Authors |
Jason M. Redman, Seth M. Steinberg, James L. Gulley |
| Abstract |
Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefits to a greater number of patients and tumor types. Metastatic castration-resistant prostate cancer (mCRPC) infrequently responds to ICIs, while the cellular vaccine approved for mCRPC, sipuleucel-T, provides a 4-month survival benefit but does not produce clinical responses as monotherapy. However, many novel and generally well-tolerated immune oncology agents with potential for immune synergy and/or additive effects are undergoing clinical development. This availability presents opportunities to develop adaptive-design combination clinical trials aimed to generate, expand, and facilitate antitumor immune responses. Here we describe a currently accruing phase I/II trial (NCT03493945) testing a brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, an IL-15 agonist, and an IDO1 inhibitor in mCRPC. This trial ( NCT03493945 ) was registered in National Clinical Trials on April 11th 2018. |
X Demographics
The data shown below were collected from the profiles of 61 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 28 | 46% |
| Saudi Arabia | 3 | 5% |
| China | 1 | 2% |
| Japan | 1 | 2% |
| Singapore | 1 | 2% |
| France | 1 | 2% |
| India | 1 | 2% |
| Sweden | 1 | 2% |
| Italy | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 21 | 34% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 37 | 61% |
| Scientists | 12 | 20% |
| Practitioners (doctors, other healthcare professionals) | 10 | 16% |
| Science communicators (journalists, bloggers, editors) | 2 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 15% |
| Student > Bachelor | 8 | 13% |
| Other | 6 | 10% |
| Student > Doctoral Student | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Other | 11 | 18% |
| Unknown | 16 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 27% |
| Biochemistry, Genetics and Molecular Biology | 8 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 23 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#1,066,773
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#244
of 3,422 outputs
Outputs of similar age
#22,812
of 351,242 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 35 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,242 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.